CAMBRIDGE, Mass., Dec. 2, 2018 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced updated results for the Phase 1 EXPLORER clinical trial of…

View more at https://www.prnewswire.com:443/news-releases/blueprint-medicines-announces-updated-results-from-ongoing-explorer-clinical-trial-of-avapritinib-demonstrating-broad-clinical-activity-and-significant-symptom-reductions-in-patients-with-systemic-mastocytosis-300758641.html